Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse.
Authors: Toutain P L, Lassourd V
Journal: Equine veterinary journal
Summary
# Editorial Summary Drug control regulations in equestrian sport face a practical dilemma: modern analytical techniques can detect therapeutic medications at trace levels long after legitimate use, yet distinguishing between residual exposure from proper treatment and intentional doping remains challenging. Toutain and Lassourd developed a non-experimental pharmacokinetic/pharmacodynamic framework to establish irrelevant plasma and urine drug concentrations (IPC and IUC)—thresholds below which detected drugs represent no meaningful performance advantage. Their approach transforms marketed therapeutic doses into effective plasma concentrations, then applies a safety factor to calculate these irrelevant thresholds, validating outputs by determining residual drug amounts and minimum withdrawal times based on published clearance data. The method identifies a critical insight: regulating based on urine concentrations is less reliable than controlling for actual drug effect, since urine is an imperfect marker of systemic exposure. For equine professionals involved in competition or therapeutic care, this framework offers a more scientifically rigorous basis for interpreting post-competition drug test results, potentially reducing false positives from legitimate medications whilst maintaining genuine doping deterrence—though practitioners should recognise that implementation requires robust withdrawal time data specific to each drug and horse population.
Read the full abstract on PubMed
Practical Takeaways
- •Regulatory authorities can use this PK/PD framework to establish detection thresholds for therapeutic medications that distinguish between legitimate therapeutic use and doping
- •Residual drug levels from legitimate medication should be distinguished from doping violations using calculated withdrawal times and concentration thresholds rather than zero-tolerance approaches
- •Compliance teams should recognize that plasma concentration monitoring is more scientifically sound than urine-based testing for determining clinically irrelevant drug residues
Key Findings
- •A pharmacokinetic/pharmacodynamic approach can determine irrelevant plasma concentrations (IPC) and irrelevant urine concentrations (IUC) for drugs in postcompetition samples without additional experimentation
- •Effective plasma concentrations (EPC) derived from marketed doses and published clearance values can be converted to IPC using an applied safety factor
- •Controlling drug effects rather than drug exposure is more demanding and appropriate for regulatory purposes than measuring absolute concentrations
- •Urine is identified as a less than ideal matrix for drug control compared to plasma-based assessments